Shares of Mallinckrodt PLC (NYSE:MNK) have been given an average rating of “Hold” by the seventeen analysts that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $10.13.
MNK has been the subject of several research analyst reports. Morgan Stanley set a $5.00 price target on shares of Mallinckrodt and gave the company a “hold” rating in a report on Friday, August 9th. Jefferies Financial Group set a $2.00 price target on shares of Mallinckrodt and gave the company a “hold” rating in a report on Friday, September 6th. ValuEngine cut shares of Mallinckrodt from a “hold” rating to a “sell” rating in a report on Tuesday, October 1st. Barclays set a $5.00 price target on shares of Mallinckrodt and gave the company a “hold” rating in a report on Tuesday, September 10th. Finally, SunTrust Banks reduced their price target on shares of Mallinckrodt to $7.00 and set a “positive” rating for the company in a report on Monday, August 12th.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Kensico Capital Management Corp acquired a new position in Mallinckrodt during the third quarter worth $1,960,000. Millennium Management LLC boosted its holdings in Mallinckrodt by 531.4% during the third quarter. Millennium Management LLC now owns 2,744,778 shares of the company’s stock worth $6,614,000 after purchasing an additional 2,310,040 shares during the last quarter. Voloridge Investment Management LLC boosted its holdings in Mallinckrodt by 200.7% during the third quarter. Voloridge Investment Management LLC now owns 736,091 shares of the company’s stock worth $1,774,000 after purchasing an additional 491,261 shares during the last quarter. Clear Creek Financial Management LLC boosted its holdings in Mallinckrodt by 31.7% during the third quarter. Clear Creek Financial Management LLC now owns 30,100 shares of the company’s stock worth $85,000 after purchasing an additional 7,250 shares during the last quarter. Finally, California State Teachers Retirement System boosted its holdings in Mallinckrodt by 8.4% during the third quarter. California State Teachers Retirement System now owns 152,945 shares of the company’s stock worth $369,000 after purchasing an additional 11,908 shares during the last quarter. Institutional investors and hedge funds own 92.05% of the company’s stock.
Shares of Mallinckrodt stock remained flat at $$3.77 on Wednesday. 6,290,570 shares of the stock traded hands, compared to its average volume of 5,105,958. The company has a market capitalization of $317.02 million, a price-to-earnings ratio of 0.47, a P/E/G ratio of 0.05 and a beta of 2.59. Mallinckrodt has a 12 month low of $1.43 and a 12 month high of $27.33. The company has a debt-to-equity ratio of 1.64, a current ratio of 1.07 and a quick ratio of 0.86. The company has a fifty day simple moving average of $3.00 and a 200-day simple moving average of $5.73.
Mallinckrodt (NYSE:MNK) last released its quarterly earnings results on Tuesday, November 5th. The company reported $2.07 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.98 by $0.09. The company had revenue of $743.70 million during the quarter, compared to analysts’ expectations of $770.56 million. Mallinckrodt had a negative net margin of 111.44% and a positive return on equity of 24.36%. The business’s quarterly revenue was down 7.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.10 earnings per share. As a group, equities analysts predict that Mallinckrodt will post 8.59 EPS for the current fiscal year.
Mallinckrodt Company Profile
Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.